Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
Add more filters










Publication year range
1.
J Allergy Clin Immunol ; 123(1): 138-145.e5, 2009 Jan.
Article in English | MEDLINE | ID: mdl-19056111

ABSTRACT

BACKGROUND: Respiratory syncytial virus (RSV)-specific IgE is a component of the host response to RSV infection, but its role in the subsequent enhancement of altered airway responsiveness is unknown. OBJECTIVE: To define the role of RSV-specific IgE in the enhancement of airway responsiveness on reinfection of newborn mice. METHODS: Mice were infected as newborns with RSV and were reinfected 5 weeks later. The role of IgE was determined by documenting RSV-specific IgE response after neonatal infection, and by assessing airway responsiveness on reinfection. RESULTS: After neonatal infection, wild-type (WT) mice developed an RSV-specific IgE response. On reinfection, these mice developed enhanced airway hyperresponsiveness (AHR), airway eosinophilia, and mucus hyperproduction, and their T-cell cytokine response was skewed toward a T(H)2 phenotype. None of these altered responses developed on reinfection of IL-4(-/-)/IL-13(-/-) mice, and no RSV-specific IgE could be detected after neonatal infection of these mice. Fc epsilon RI(-/-) mice did not develop the enhanced AHR on reinfection, and airway eosinophilia and mucus production were significantly attenuated. These responses could be restored in deficient mice reconstituted with WT mast cells. In RSV-infected newborn WT mice, administration of anti-IgE prevented the enhancement of AHR and attenuated eosinophilia and mucus hyperproduction on reinfection, an effect that was associated with diminished T(H)2 cytokine production and increased IFN-gamma production. CONCLUSION: Respiratory syncytial virus-specific IgE enhances the development of T(H)2-biased airway responsiveness on reinfection of mice initially infected as newborns.


Subject(s)
Antibodies, Viral/immunology , Immunoglobulin E/immunology , Respiratory Hypersensitivity/immunology , Respiratory Syncytial Virus Infections/immunology , Respiratory Syncytial Viruses/immunology , Th2 Cells/immunology , Animals , Animals, Newborn , Interleukin-13/genetics , Interleukin-13/immunology , Interleukin-4/genetics , Interleukin-4/immunology , Mice , Mice, Inbred BALB C , Mice, Knockout , Receptors, IgE/genetics , Receptors, IgE/immunology , Respiratory Hypersensitivity/genetics , Respiratory Hypersensitivity/virology , Respiratory Syncytial Virus Infections/genetics
2.
J Allergy Clin Immunol ; 121(1): 88-94, 2008 Jan.
Article in English | MEDLINE | ID: mdl-17936889

ABSTRACT

BACKGROUND: RNA interference is an endogenous cellular mechanism in which short interfering RNAs (siRNAs) direct the sequence specific degradation of a target mRNA. siRNAs can be synthesized with chemical modifications to increase stability and reduce double-stranded RNA-induced immune responses without affecting their ability to elicit degradation of target mRNA. OBJECTIVES: This study examined the use of chemically modified siRNAs in a mouse model of allergen-induced airway hyperresponsiveness. METHODS: Chemically modified siRNAs were designed and screened in a cell-based reporter assay. The most potent siRNAs were then screened in bone marrow-derived mast cells to demonstrate efficacy in primary cells. RESULTS: A candidate siRNA was formulated and administered to sensitized mice just before airway challenge with allergen. Administration of the siRNA was shown to reduce airway resistance significantly in sensitized and challenged mice by 60%, whereas a control siRNA had no effect. CONCLUSION: These data demonstrate the effectiveness of introducing targeted siRNAs to prevent induction of allergen-induced airway dysfunction and suggest potential therapeutic applications.


Subject(s)
Bronchial Hyperreactivity/therapy , Interleukin-13/metabolism , RNA Interference , RNA, Small Interfering/therapeutic use , Animals , Bone Marrow Cells , Bronchial Hyperreactivity/etiology , Disease Models, Animal , Female , Genes, Reporter , Humans , Interleukin-13/genetics , Mast Cells , Mice , Mice, Inbred BALB C , RNA, Small Interfering/chemical synthesis , RNA, Small Interfering/genetics , RNA, Small Interfering/metabolism , Specific Pathogen-Free Organisms , Treatment Outcome
3.
Am J Respir Cell Mol Biol ; 38(5): 501-8, 2008 May.
Article in English | MEDLINE | ID: mdl-18063836

ABSTRACT

The female hormone estrogen is an important factor in the regulation of airway function and inflammation, and sex differences in the prevalence of asthma are well described. Using an animal model, we determined how sex differences may underlie the development of altered airway function in response to allergen exposure. We compared sex differences in the development of airway hyperresponsiveness (AHR) after allergen exposure exclusively via the airways. Ovalbumin (OVA) was administered by nebulization on 10 consecutive days in BALB/c mice. After methacholine challenge, significant AHR developed in male mice but not in female mice. Ovariectomized female mice showed significant AHR after 10-day OVA inhalation. ICI182,780, an estrogen antagonist, similarly enhanced airway responsiveness even when administered 1 hour before assay. In contrast, 17beta-estradiol dose-dependently suppressed AHR in male mice. In all cases, airway responsiveness was inhibited by the administration of a neurokinin 1 receptor antagonist. These results demonstrate that sex differences in 10-day OVA-induced AHR are due to endogenous estrogen, which negatively regulates airway responsiveness in female mice. Cumulatively, the results suggest that endogenous estrogen may regulate the neurokinin 1-dependent prejunctional activation of airway smooth muscle in allergen-exposed mice.


Subject(s)
Allergens/administration & dosage , Bronchial Hyperreactivity/immunology , Bronchial Hyperreactivity/physiopathology , Estrogens/physiology , Ovalbumin/administration & dosage , Sex Characteristics , Allergens/immunology , Animals , Bronchial Hyperreactivity/metabolism , Disease Models, Animal , Estradiol/administration & dosage , Estradiol/analogs & derivatives , Estrogen Receptor Modulators/administration & dosage , Female , Fulvestrant , Male , Methacholine Chloride/administration & dosage , Mice , Mice, Inbred BALB C , Neurokinin A/antagonists & inhibitors , Neurokinin A/physiology , Neurokinin-1 Receptor Antagonists , Ovalbumin/immunology
4.
Am J Respir Crit Care Med ; 177(2): 208-18, 2008 Jan 15.
Article in English | MEDLINE | ID: mdl-17962634

ABSTRACT

RATIONALE: Severe respiratory syncytial virus (RSV) bronchiolitis has been associated with deficient IFN-gamma production in humans, but the role of this cytokine in determining the outcome of reinfection is unknown. OBJECTIVES: To define the role of IFN-gamma in the development of RSV-mediated airway hyperresponsiveness (AHR) and lung histopathology in mice. METHODS: Wild-type (WT) and IFN-gamma knockout mice were infected with RSV in the newborn or weaning stages and reinfected 5 weeks later. Airway responses were assessed on Day 6 after the primary or secondary infection. MEASUREMENTS AND MAIN RESULTS: Both WT and IFN-gamma knockout mice developed similar levels of AHR and airway inflammation after primary infection. After reinfection, IFN-gamma knockout mice, but not WT mice, developed AHR, airway eosinophilia, and mucus hyperproduction. Intranasal administration of IFN-gamma during primary infection but not during reinfection prevented the development of these altered airway responses on reinfection in IFN-gamma knockout mice. Adoptive transfer of WT T cells into IFN-gamma knockout mice before primary infection restored IFN-gamma production in the lungs and prevented the development of altered airway responses on reinfection. Treatment of mice with IFN-gamma during primary neonatal infection prevented the enhancement of AHR and the development of airway eosinophilia and mucus hyperproduction on reinfection. CONCLUSIONS: IFN-gamma production during primary RSV infection is critical to the development of protection against AHR and lung histopathology on reinfection. Provision of IFN-gamma during primary infection in infancy may be a potential therapeutic approach to alter the course of RSV-mediated long-term sequelae.


Subject(s)
Interferon-gamma/biosynthesis , Lung/metabolism , Respiratory Syncytial Virus Infections/metabolism , Respiratory Syncytial Viruses , Animals , Animals, Newborn , Bronchial Hyperreactivity/etiology , Bronchial Hyperreactivity/prevention & control , Interferon-gamma/deficiency , Interferon-gamma/genetics , Interferon-gamma/therapeutic use , Lung/pathology , Lung/virology , Mice , Mice, Knockout , Recurrence , Respiratory Syncytial Virus Infections/etiology , Respiratory Syncytial Virus Infections/pathology , Respiratory Syncytial Viruses/isolation & purification , T-Lymphocytes/immunology , Viral Load
5.
J Immunol ; 179(5): 2787-96, 2007 Sep 01.
Article in English | MEDLINE | ID: mdl-17709492

ABSTRACT

CD4+ T cells, particularly Th2 cells, play a pivotal role in allergic airway inflammation. However, the requirements for interactions between CD4+ and CD8+ T cells in airway allergic inflammation have not been delineated. Sensitized and challenged OT-1 mice in which CD8+ T cells expressing the transgene for the OVA(257-264) peptide (SIINFEKL) failed to develop airway hyperresponsiveness (AHR), airway eosinophilia, Th2 cytokine elevation, or goblet cell metaplasia. OT-1 mice that received naive CD4+IL-4+ T cells but not CD4+IL-4- T cells before sensitization developed all of these responses to the same degree as wild-type mice. Moreover, recipients of CD4+IL-4+ T cells developed significant increases in the number of CD8+IL-13+ T cells in the lung, whereas sensitized OT-1 mice that received primed CD4+ T cells just before challenge failed to develop these responses. Sensitized CD8-deficient mice that received CD8+ T cells from OT-1 mice that received naive CD4+ T cells before sensitization increased AHR and eosinophil numbers in bronchoalveolar lavage fluid when challenged with allergen. In contrast, sensitized CD8-deficient mice receiving CD8+ T cells from OT-1 mice without CD4+ T cells developed reduced AHR and eosinophil numbers in bronchoalveolar lavage fluid when challenged. These data suggest that interactions between CD4+ and CD8+ T cells, in part through IL-4 during the sensitization phase, are essential to the development of CD8+IL-13+ T cell-dependent AHR and airway allergic inflammation.


Subject(s)
Asthma/immunology , Bronchial Hyperreactivity/immunology , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Interleukin-4/metabolism , Adoptive Transfer , Animals , Asthma/prevention & control , Bronchial Hyperreactivity/prevention & control , CD4 Antigens/analysis , Egg Proteins/genetics , Egg Proteins/metabolism , Inflammation/immunology , Inflammation/prevention & control , Interleukin-4/administration & dosage , Interleukin-4/genetics , Mice , Mice, Transgenic , Ovalbumin/genetics , Ovalbumin/metabolism , Peptide Fragments , Transgenes
6.
J Allergy Clin Immunol ; 119(5): 1241-50, 2007 May.
Article in English | MEDLINE | ID: mdl-17353041

ABSTRACT

BACKGROUND: IL-10 affects dendritic cell (DC) function, but the effects on airway hyperresponsiveness (AHR) and inflammation are not defined. OBJECTIVE: We sought to determine the importance of IL-10 in regulating DC function in allergen-induced AHR and airway inflammation. METHODS: DCs were generated from bone marrow in the presence or absence of IL-10. In vivo IL-10-treated DCs from IL-10(+/+) and IL-10(-/-) donors pulsed with ovalbumin (OVA) were transferred to naive or sensitized mice before challenge. In recipient mice AHR, cytokine levels, cell composition of bronchoalveolar lavage (BAL) fluid, and lung histology were monitored. RESULTS: In vitro, IL-10-treated DCs expressed lower levels of CD11c, CD80, and CD86; expressed lower levels of IL-12; and suppressed T(H)2 cytokine production. In vivo, after transfer of OVA-pulsed IL-10-treated DCs, naive mice did not have AHR, airway eosinophilia, T(H)2 cytokine increase in BAL fluid, or goblet cell metaplasia when challenged, and in sensitized and challenged mice IL-10-treated DCs suppressed these responses. Levels of IL-10 in BAL fluid and numbers of lung CD4(+)IL-10(+) T cells were increased in mice that received OVA-pulsed IL-10-treated DCs. Transfer of IL-10-treated DCs from IL-10-deficient mice were ineffective in suppressing the responses in sensitized and challenged mice. CONCLUSIONS: These data demonstrate that IL-10-treated DCs are potent suppressors of the development of AHR, inflammation, and T(H)2 cytokine production; these regulatory functions are at least in part through the induction of endogenous (DC) production of IL-10. CLINICAL IMPLICATIONS: Modification of DC function by IL-10 can attenuate lung allergic responses, including the development of AHR.


Subject(s)
Bronchial Hyperreactivity/immunology , Dendritic Cells/immunology , Inflammation/immunology , Interleukin-10/metabolism , Adoptive Transfer , Animals , Cytokines/biosynthesis , Dendritic Cells/metabolism , Female , Flow Cytometry , Immunohistochemistry , Mice , Ovalbumin/immunology
7.
Am J Respir Cell Mol Biol ; 35(2): 147-54, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16528011

ABSTRACT

RANTES (CC chemokine ligand 5) contributes to airway inflammation through accumulation of eosinophils, but the exact role of RANTES (CCL5) is not defined. C57BL/6 mice, sensitized by injection of ovalbumin (OVA) on Days 1 and 14, were challenged with OVA on Days 28, 29, and 30 (3 challenges, short-term-challenge model) or on Days 28, 29, 30, 36, 40, 44, and 48 (7 challenges, repeated-challenge model) and evaluated 48 h later. Anti-mouse RANTES was given intravenously, and recombinant mouse RANTES or PBS was given intratracheally. These reagents were given on Days 28, 29, and 30 in the short-term-challenge study and on Days 44 and 48 in the repeated-challenge study. After short-term challenge, there were no effects after administration of anti-RANTES or RANTES. In the repeated-challenge study, although control mice showed a decrease in airway hyperresponsiveness, administration of anti-RANTES sustained and enhanced airway hyperresponsiveness and increased goblet cell numbers. In contrast, administration of RANTES normalized airway function but reduced goblet cell numbers. IL-12 and IFN-gamma levels in BAL decreased in the anti-RANTES group and increased in the RANTES group. IFN-gamma-producing CD4 T cells in lung, and IFN-gamma production from lung T cells in response to OVA in the anti-RANTES group, were significantly decreased but were increased in the RANTES group. Anti-IFN-gamma, administered with RANTES, decreased the effects of RANTES on AHR after repeated challenge. These data indicate that RANTES plays a role in the regulation of airway function after repeated allergen challenge, in part through modulation of levels of IFN-gamma and IL-12.


Subject(s)
Allergens/immunology , Chemokine CCL5/physiology , Ovalbumin/immunology , Respiratory Hypersensitivity/immunology , Animals , Bronchoalveolar Lavage Fluid/immunology , Chemokine CCL5/administration & dosage , Chemokine CCL5/antagonists & inhibitors , Chemokine CCL5/genetics , Chemokine CCL5/immunology , Female , Interferon-gamma/analysis , Interferon-gamma/biosynthesis , Interleukin-12/analysis , Interleukin-12/biosynthesis , Mice , Mice, Inbred C57BL , Ovalbumin/administration & dosage , Recombinant Proteins/administration & dosage , Recombinant Proteins/metabolism
8.
J Immunol ; 175(3): 1876-83, 2005 Aug 01.
Article in English | MEDLINE | ID: mdl-16034131

ABSTRACT

Respiratory syncytial virus (RSV) infection in early life is suspected to play a role in the development of post-bronchiolitis wheezing and asthma. Reinfection is common at all ages, but factors that determine the development of altered airway function after reinfection are not well understood. This study was conducted in a mouse model to define the role of age in determining the consequences on airway function after reinfection. Mice were infected shortly after birth or at weaning and were reinfected 5 wk later, followed by assessment of airway function, airway inflammation, and lung histopathology. Infection of mice at weaning elicited a protective airway response upon reinfection. In this age group, reinfection resulted in increased airway inflammation, but without development of airway hyperresponsiveness (AHR) or eosinophilia and decreased IL-13 levels. By contrast, neonatal infection failed to protect the airways and resulted in enhanced AHR after reinfection. This secondary response was associated with the development of airway eosinophilia, increased IL-13 levels, and mucus hyperproduction. Both CD4- and CD8-positive T cells were a source of IL-13 in the lung, and inhibition of IL-13 abolished AHR and mucus production in these mice. Inoculation of UV-inactivated virus failed to elicit these divergent responses to reinfection, emphasizing the requirement for active lung infection during initial exposure. Thus, neonatal RSV infection predisposes to the development of airway eosinophilia and enhanced AHR via an IL-13-dependent mechanism during reinfection, whereas infection at a later age protects against the development of these altered airway responses after reinfection.


Subject(s)
Aging/immunology , Animals, Newborn/immunology , Animals, Newborn/virology , Bronchial Hyperreactivity/immunology , Bronchial Hyperreactivity/physiopathology , Interleukin-13/biosynthesis , Respiratory Syncytial Virus Infections/immunology , Respiratory Syncytial Virus Infections/physiopathology , Animals , Bronchial Hyperreactivity/prevention & control , Disease Models, Animal , Disease Susceptibility/immunology , Disease Susceptibility/physiopathology , Eosinophilia/immunology , Eosinophilia/physiopathology , Eosinophilia/virology , Interleukin-13/physiology , Mice , Mice, Inbred BALB C , Recurrence , Respiratory Syncytial Virus Infections/prevention & control , Weaning
9.
Am J Physiol Lung Cell Mol Physiol ; 288(4): L761-70, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15608150

ABSTRACT

The mechanisms by which respiratory syncytial virus (RSV) infection causes airway hyperresponsiveness (AHR) are not fully established. We hypothesized that RSV infection may alter the expression of airway sensory neuropeptides, thereby contributing to the development of altered airway function. BALB/c mice were infected with RSV followed by assessment of airway function, inflammation, and sensory neuropeptide expression. After RSV infection, mice developed significant airway inflammation associated with increased airway resistance to inhaled methacholine and increased tracheal smooth muscle responsiveness to electrical field stimulation. In these animals, substance P expression was markedly increased, whereas calcitonin gene-related peptide (CGRP) expression was decreased in airway tissue. Prophylactic treatment with Sendide, a highly selective antagonist of the neurokinin-1 receptor, or CGRP, but not the CGRP antagonist CGRP(8-37), inhibited the development of airway inflammation and AHR in RSV-infected animals. Therapeutic treatment with CGRP, but not CGRP(8-37) or Sendide, abolished AHR in RSV-infected animals despite increased substance P levels and previously established airway inflammation. These data suggest that RSV-induced airway dysfunction is, at least in part, due to an imbalance in sensory neuropeptide expression in the airways. Restoration of this balance may be beneficial for the treatment of RSV-mediated airway dysfunction.


Subject(s)
Calcitonin Gene-Related Peptide/metabolism , Lung/metabolism , Pyrrolidonecarboxylic Acid/analogs & derivatives , Respiratory Hypersensitivity/immunology , Respiratory Hypersensitivity/virology , Respiratory Syncytial Virus Infections/immunology , Respiratory Syncytial Virus Infections/pathology , Respiratory Syncytial Virus, Human/pathogenicity , Animals , Antiemetics/pharmacology , Calcitonin Gene-Related Peptide/antagonists & inhibitors , Calcitonin Gene-Related Peptide/genetics , Humans , Inflammation/etiology , Lung/immunology , Lung/pathology , Mice , Mice, Inbred BALB C , Neurokinin-1 Receptor Antagonists , Peptide Fragments/pharmacology , Pyrrolidonecarboxylic Acid/pharmacology , Substance P/pharmacology
10.
J Allergy Clin Immunol ; 114(4): 820-5, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15480321

ABSTRACT

BACKGROUND: Eosinophils play a major role in allergic airway inflammation because of their ability to release toxic mediators. In addition, they are able to migrate toward draining thoracic lymph nodes (TLNs) after intratracheal administration, where they can function as antigen-presenting cells. OBJECTIVE: In this study, we evaluated in vivo eosinophil migration toward the TLN after allergen sensitization and analyzed expression of molecules involved in antigen presentation. METHODS: Mice were sensitized by intraperitoneal injection of ovalbumin on days 1 and 10 and challenged once intranasally with ovalbumin on day 20. The kinetics of eosinophilia was evaluated in blood, lung tissue homogenate, bronchoalveolar lavage fluid, and TLN. Cell surface staining was analyzed by flow cytometry. RESULTS: The kinetics of eosinophil recruitment was similar in TLN, lung tissue, and blood, beginning at 12 hours and peaking at 48 hours after allergen challenge. Approximately 70% of TLN eosinophils expressed MHC class II molecules, compared with less than 25% in blood and lungs. Moreover, TLN eosinophils expressed higher levels of MHC class II and CD86 compared with blood and lung eosinophils. Most eosinophils expressed CD80 and CD54, whereas only a few eosinophils expressed CD40. Eosinophils in lungs and TLN appeared to be activated with lower CD62-ligand expression compared with blood eosinophils. CONCLUSION: The presence of eosinophils with a different phenotype in the TLN at early time points after allergen challenge of sensitized mice supports their capacity to serve as antigen-presenting cells, sustaining allergic/inflammatory responses in the airways.


Subject(s)
Allergens/immunology , Chemotaxis, Leukocyte/immunology , Eosinophils/immunology , Lymph Nodes/immunology , Administration, Inhalation , Allergens/administration & dosage , Animals , Antigen Presentation/immunology , Antigens, CD/immunology , Bronchial Provocation Tests , Female , Genes, MHC Class II/immunology , Mice , Thorax
11.
Am J Respir Crit Care Med ; 170(9): 952-9, 2004 Nov 01.
Article in English | MEDLINE | ID: mdl-15306536

ABSTRACT

Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis during infancy and is associated with subsequent wheezing and asthma, but the nature of this association is not fully understood. We investigated the role of RSV-specific IgE antibodies in the pathophysiology of virus-induced airway dysfunction in a mouse model. Lung infection with RSV resulted in significant increases in mRNA expression for IgE and both of its high- and low-affinity receptors. In serum, virus-specific IgE antibodies reached peak levels by Day 21 after infection. Data from in vitro experiments show that RSV can induce mast cell degranulation, but only if these cells are sensitized with specific IgE. When passively sensitized in vivo with virus-specific IgE, mice developed exaggerated airway responsiveness to methacholine on airway infection, an effect that required the high-affinity receptor of IgE. These data suggest that RSV-specific IgE may contribute to the pathophysiology of airway dysfunction in children who develop this class of specific antibody.


Subject(s)
Antibodies, Viral/analysis , Asthma/physiopathology , Bronchial Hyperreactivity/immunology , Immunoglobulin E/immunology , Respiratory Syncytial Virus Infections/immunology , Animals , Asthma/immunology , Base Sequence , Bronchial Hyperreactivity/virology , Bronchoalveolar Lavage Fluid/immunology , Disease Models, Animal , Female , Male , Mice , Mice, Inbred BALB C , Molecular Sequence Data , Polymerase Chain Reaction , Probability , RNA, Messenger/analysis , Respiratory Syncytial Virus Infections/physiopathology , Respiratory Syncytial Viruses/immunology , Sensitivity and Specificity
12.
J Immunol ; 173(2): 1298-306, 2004 Jul 15.
Article in English | MEDLINE | ID: mdl-15240723

ABSTRACT

Age is an important factor in determining the quantity and quality of immune responses when challenged with allergen. In a model of allergen-induced airway hyperresponsiveness and inflammation, where the sensitization phase and challenge phases can be dissociated in time, we examined the impact of age on these two phases. Sensitization of young mice (1-20 wk), but not older animals (30-40 wk), led to the development of airway hyperresponsiveness, airway eosinophilia, Th2 cytokine responses, and allergen-specific IgE, regardless of the age when the challenge phase was conducted. Thus, age at the time of initial sensitization was shown to be the critical factor dictating the nature of the response to later allergen challenge, as older mice remained responsive to allergen challenge if sensitized at a young age. These effects were shown to be mediated by lung T cells from sensitized young mice. Moreover, the failure of old sensitized mice to mediate these effects was shown not to be the result of active suppression of the responses. These data define the importance of age at initial allergen exposure in dictating subsequent responses in the lung when exposed to allergen and may help to define why asthma, even in adults, is most often initiated in early childhood.


Subject(s)
Allergens/immunology , Hypersensitivity/immunology , Respiratory System/immunology , Age Factors , Animals , Cytokines/metabolism , Mice , Respiratory System/metabolism
13.
Am J Respir Cell Mol Biol ; 30(6): 830-6, 2004 Jun.
Article in English | MEDLINE | ID: mdl-14754758

ABSTRACT

The role of an interleukin (IL)-1 receptor antagonist (IL-1Ra) on the development of airway hyperresponsiveness (AHR) and airway inflammation following acute O(3) exposure in mice was investigated. Exposure of C57/BL6 mice to O(3) at a concentration of 2.0 ppm or filtered air for 3 h resulted in increases in airway responsiveness to inhaled methacholine (MCh) 8 and 16 h after the exposure, and an increase in neutrophils in the bronchoalveolar lavage (BAL) fluid. IL-1beta expression, assessed by gene microarray, was increased 2-fold 4 h after O(3) exposure, and returned to baseline levels by 24 h. Levels of IL-1beta in lung homogenates were also increased 8 h after O(3) exposure. Administration of (human) IL-1Ra before and after O(3) exposure prevented development of AHR and decreased BAL fluid neutrophilia. Increases in chemokine levels in lung homogenates, tumor necrosis factor-alpha, MIP-2, and keratinocyte chemoattractant following O(3) exposure were prevented by IL-1Ra. Inhalation of dexamethasone, an inhibitor of IL-1 production, blocked the development of AHR, BAL fluid neutrophilia, and decreased levels of IL-1 following O(3) exposure. In summary, acute exposure to O(3) induces AHR, neutrophilic inflammation, epithelial damage, and IL-1. An IL-1Ra effectively prevents the development of altered airway function, inflammation, and structural damage.


Subject(s)
Bronchial Hyperreactivity/immunology , Ozone/immunology , Receptors, Interleukin-1/antagonists & inhibitors , Receptors, Interleukin-1/immunology , Animals , Bronchoalveolar Lavage Fluid/chemistry , Bronchoalveolar Lavage Fluid/cytology , Bronchoconstrictor Agents/pharmacology , Cytokines/metabolism , Dexamethasone/pharmacology , Female , Gene Expression Profiling , Gene Expression Regulation , Glucocorticoids/pharmacology , Humans , Interleukin-1/genetics , Interleukin-1/metabolism , Methacholine Chloride/pharmacology , Mice , Mice, Inbred C57BL , Neutrophils/immunology , Neutrophils/metabolism , Oxidants, Photochemical/pharmacology , Ozone/pharmacology , Respiratory Mucosa/cytology , Respiratory Mucosa/drug effects , Respiratory Mucosa/metabolism , Respiratory Mucosa/pathology
14.
J Immunol ; 172(4): 2549-58, 2004 Feb 15.
Article in English | MEDLINE | ID: mdl-14764728

ABSTRACT

The role of Th2/CD4 T cells, which secrete IL-4, IL-5, and IL-13, in allergic disease is well established; however, the role of CD8(+) T cells (allergen-induced airway hyperresponsiveness (AHR) and inflammation) is less clear. This study was conducted to define the role of Ag-primed CD8(+) T cells in the development of these allergen-induced responses. CD8-deficient (CD8(-/-)) mice and wild-type mice were sensitized to OVA by i.p. injection and then challenged with OVA via the airways. Compared with wild-type mice, CD8(-/-) mice developed significantly lower airway responsiveness to inhaled methacholine and lung eosinophilia, and exhibited decreased IL-13 production both in vivo, in the bronchoalveolar lavage (BAL) fluid, and in vitro, following Ag stimulation of peribronchial lymph node (PBLN) cells in culture. Reconstitution of sensitized and challenged CD8(-/-) mice with allergen-sensitized CD8(+) T cells fully restored the development of AHR, BAL eosinophilia, and IL-13 levels in BAL and in culture supernatants from PBLN cells. In contrast, transfer of naive CD8(+) T cells or allergen-sensitized CD8(+) T cells from IL-13-deficient donor mice failed to do so. Intracellular cytokine staining of lung as well as PBLN T cells revealed that CD8(+) T cells were a source of IL-13. These data suggest that Ag-primed CD8(+) T cells are required for the full development of AHR and airway inflammation, which appears to be associated with IL-13 production from these primed T cells.


Subject(s)
Antigens/administration & dosage , Bronchial Hyperreactivity/immunology , CD8-Positive T-Lymphocytes/immunology , Interleukin-13/physiology , Lung/pathology , Ovalbumin/immunology , Administration, Inhalation , Adoptive Transfer , Animals , Antigens/immunology , Bronchial Hyperreactivity/genetics , Bronchial Hyperreactivity/pathology , Bronchoalveolar Lavage Fluid/immunology , CD8 Antigens/genetics , CD8-Positive T-Lymphocytes/metabolism , CD8-Positive T-Lymphocytes/transplantation , Cell Division/immunology , Cells, Cultured , Cytokines/biosynthesis , Cytokines/metabolism , Female , Immunoglobulin E/biosynthesis , Inflammation/genetics , Inflammation/immunology , Injections, Intraperitoneal , Interleukin-13/biosynthesis , Interleukin-13/deficiency , Interleukin-13/genetics , Lung/immunology , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Ovalbumin/administration & dosage
15.
J Allergy Clin Immunol ; 112(6): 1078-87, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14657862

ABSTRACT

BACKGROUND: IL-13 is a central mediator of allergen-induced airway hyperresponsiveness (AHR), but its role in respiratory syncytial virus (RSV)-induced AHR is not defined. The combination of allergen exposure and RSV infection is known to increase AHR and lung inflammation, but whether IL-13 regulates this increase is similarly not known. OBJECTIVE: Our objective was to determine the role of RSV infection and IL-13 on airway responsiveness and lung inflammation on sensitized and challenged mice. METHODS: Using a murine model of RSV infection and allergen exposure, we examined the role of IL-13 in the development of AHR and lung inflammation in IL-13 knockout mice, as well as using a potent IL-13 inhibitor (IL-13i). Mice were sensitized and challenged to allergen, and 6 days after the last challenge, they were infected with RSV. IL-13 was inhibited using an IL-13 receptor alpha(2)-human IgG fusion protein. AHR to inhaled methacholine was measured 6 days after infection, as was bronchoalveolar lavage fluid and lung inflammatory and cytokine responses. RESULTS: RSV-induced AHR was unaffected by the IL-13i, despite prevention of goblet cell hyperplasia. Similar results were seen in IL-13-deficient mice. In sensitized and challenged mice, RSV infection significantly increased AHR, and after IL-13i treatment, AHR was significantly reduced, but to the levels seen in RSV-infected mice alone. CONCLUSIONS: These results indicate that despite some similarities, the mechanisms leading to AHR induced by RSV are different from those that follow allergen sensitization and challenge. Because IL-13 inhibition is effective in preventing the increases in AHR and mucus production in sensitized and challenged mice infected with RSV, IL-13i could play an important role in preventing the consequences of viral infection in patients with allergic asthma.


Subject(s)
Allergens/immunology , Bronchial Hyperreactivity/etiology , Interleukin-13/immunology , Respiratory Syncytial Virus Infections/immunology , Respiratory Syncytial Virus, Human/pathogenicity , Animals , Bronchoalveolar Lavage Fluid/cytology , Bronchoalveolar Lavage Fluid/immunology , Cytokines/biosynthesis , Cytokines/immunology , Disease Models, Animal , Female , Humans , Interleukin-13/biosynthesis , Mice , Mice, Inbred BALB C , Ovalbumin/administration & dosage , Ovalbumin/immunology , Respiratory Syncytial Virus Infections/virology
16.
Am J Respir Crit Care Med ; 168(11): 1333-41, 2003 Dec 01.
Article in English | MEDLINE | ID: mdl-14500265

ABSTRACT

Studies in murine models have suggested the involvement of the complement anaphylatoxins (C3a and C5a) in the development of allergic asthma. We investigated the effects of inhibiting complement activation after sensitization but before allergen challenge on the development of allergic airway inflammation and airway hyperresponsiveness. To prevent complement activation, we used a recombinant soluble form of the mouse membrane complement inhibitor complement receptor-related gene y (Crry) fused to the IgG1 hinge, CH2 and CH3 domains (Crry-Ig), which has decay-accelerating activity for both the classic and alternative pathways of complement as well as cofactor activity for factor I-mediated cleavage of C3b and C4b. C57BL/6 mice were sensitized (Days 1 and 14) and challenged (Days 24-26) with ovalbumin. Crry-Ig was administered after allergen sensitization either as an intraperitoneal injection or by nebulization before allergen challenge. Crry-Ig significantly prevented the development of airway hyperresponsiveness, decreased airway and lung eosinophilia as well as the numbers of lung lymphocytes, decreased levels of interleukin (IL)-4, IL-5, and IL-13 in bronchoalveolar lavage fluid and decreased serum ovalbumin-specific IgE and IgG1. These results suggest that prevention of complement activation may have a therapeutic role in the treatment of allergic airway inflammation and asthma in sensitized individuals.


Subject(s)
Complement Pathway, Alternative/drug effects , Complement Pathway, Classical/drug effects , Immunoglobulin G/administration & dosage , Proteins/administration & dosage , Receptors, Complement/administration & dosage , Respiratory Hypersensitivity/drug therapy , Animals , Bronchial Provocation Tests , Disease Models, Animal , Female , Inflammation/drug therapy , Mice , Mice, Inbred C57BL , Receptors, Complement 3b
17.
Am J Respir Crit Care Med ; 168(7): 783-9, 2003 Oct 01.
Article in English | MEDLINE | ID: mdl-12882759

ABSTRACT

The lung collectin surfactant protein D (SP-D) is an important component of the innate immune response but is also believed to play a role in other regulatory aspects of immune and inflammatory responses within the lung. The role of SP-D in the development of allergen-induced airway inflammation and hyperresponsiveness (AHR) is not well defined. SP-D levels progressively increased up to 48 hours after allergen challenge of sensitized mice and then subsequently decreased. The levels of SP-D paralleled the development of airway eosinophilia and AHR. To determine if this association was functionally relevant, mice were administered rat SP-D (rSP-D) intratracheally. When given to sensitized mice before challenge, AHR and eosinophilia were reduced by rSP-D in a dose-dependent manner but not by mutant rSP-D. rSP-D administration resulted in increased levels of interleukin (IL)-10, IL-12, and IFN-gamma in bronchoalveolar lavage fluid and reduced goblet cell hyperplasia. Culture of alveolar macrophages together with SP-D and allergen resulted in increased production of IL-10, IL-12, and IFN-gamma. These results indicate that SP-D can (negatively) regulate the development of AHR and airway inflammation after airway challenge of sensitized mice, at least in part, by modulating the function of alveolar macrophages.


Subject(s)
Asthma/prevention & control , Bronchial Hyperreactivity/prevention & control , Pulmonary Surfactant-Associated Protein D/therapeutic use , Pulmonary Surfactants/therapeutic use , Animals , Asthma/metabolism , Asthma/physiopathology , Bronchial Hyperreactivity/etiology , Bronchial Hyperreactivity/metabolism , Bronchial Provocation Tests , Bronchoalveolar Lavage Fluid/chemistry , Bronchoalveolar Lavage Fluid/cytology , Cytokines/metabolism , Female , Macrophages, Alveolar/drug effects , Macrophages, Alveolar/physiology , Mice , Mice, Inbred BALB C , Pulmonary Surfactant-Associated Protein D/metabolism , Pulmonary Surfactant-Associated Protein D/pharmacology , Pulmonary Surfactants/pharmacology
18.
J Immunol ; 170(8): 4301-9, 2003 Apr 15.
Article in English | MEDLINE | ID: mdl-12682266

ABSTRACT

Following allergen challenge of sensitized mice, neutrophils are the first inflammatory cells found in bronchoalveolar lavage (BAL) fluid. To determine the underlying mechanism for their accumulation, mice were sensitized to OVA on days 0 and 14, and received, on day 28, a single intranasal challenge (s.i.n.) with either OVA or ragweed. Eight hours after the s.i.n., BAL fluid was obtained. BALB/c mice sensitized and challenged with OVA showed significantly higher total cell counts and numbers of neutrophils in BAL fluid compared to the OVA-sensitized and ragweed-challenged or nonsensitized mice. Levels of neutrophil chemokines in BAL fluid supernatants were markedly elevated in the sensitized and OVA-challenged mice; Fc epsilon RI-deficient mice showed comparable numbers of neutrophils and neutrophil chemokines in BAL fluid after s.i.n. But in sensitized mice lacking the Fc common gamma-chain and B cell-deficient mice, the number of neutrophils and levels of neutrophil chemokines in BAL fluid were significantly lower. Further, mice lacking the FcgammaRIII did not develop this early neutrophil influx. Neutrophil infiltration could be induced in naive mice following intranasal instillation of allergen combined with allergen-specific IgG1. In addition, macrophages from sensitized mice were stimulated with allergen and activated to produce neutrophil chemokines. These results demonstrate that neutrophil influx after allergen challenge requires prior sensitization, is allergen-specific, is mediated through FcgammaRIII, and is dependent on the presence of Ab.


Subject(s)
Allergens/administration & dosage , Allergens/immunology , Antibody Specificity , Immunoglobulin E/physiology , Immunoglobulin G/physiology , Neutrophil Infiltration/immunology , Receptors, IgG/physiology , Administration, Intranasal , Agammaglobulinemia/genetics , Agammaglobulinemia/immunology , Agammaglobulinemia/pathology , Ambrosia/immunology , Animals , Antibody Specificity/genetics , B-Lymphocytes/immunology , B-Lymphocytes/pathology , Bronchoalveolar Lavage Fluid/cytology , Bronchoalveolar Lavage Fluid/immunology , Cells, Cultured , Chemokines/blood , Chemokines/metabolism , Epitopes/immunology , Female , Immunization , Immunoglobulin G/metabolism , Lymphopenia/genetics , Lymphopenia/immunology , Lymphopenia/pathology , Macrophages, Alveolar/immunology , Macrophages, Alveolar/metabolism , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Knockout , Neutrophil Infiltration/genetics , Neutrophils/immunology , Neutrophils/metabolism , Ovalbumin/administration & dosage , Ovalbumin/immunology , Receptors, IgG/deficiency , Receptors, IgG/genetics
19.
J Immunol ; 169(11): 6482-9, 2002 Dec 01.
Article in English | MEDLINE | ID: mdl-12444158

ABSTRACT

The effectiveness of targeting IL-13 in models where airway hyperresponsiveness (AHR) and airway inflammation have already been established is not well-described. We investigated the effects of blocking IL-13 on the early and late phase airway responses and the development of AHR in previously sensitized and challenged mice. BALB/cByJ mice were sensitized (days 1 and 14) and challenged (days 28-30) with OVA. Six weeks later (day 72), previously sensitized/challenged mice were challenged with a single OVA aerosol and the early and late phase response and development of AHR were determined. Specific in vivo blockade of IL-13 was attained after i.p. injection of a soluble IL-13Ralpha2-IgG fusion protein (sIL-13Ralpha2Fc) on days 71-72 for the early and late responses and on days 71-73 for the development of AHR. sIL-13Ralpha2Fc administration inhibited the late, but not early, phase response and the OVA challenge-induced changes in lung resistance and dynamic compliance; as well, sIL-13Ralpha2Fc administration decreased bronchoalveolar lavage eosinophilia and mucus hypersecretion following the secondary challenge protocols. These results demonstrate that targeting IL-13 alone regulates airway responses when administrated to mice with established allergic airway disease. These data identify the importance of IL-13 in the development of allergen-induced altered airway responsiveness following airway challenge, even when administered before rechallenge of mice in which allergic disease had been previously established.


Subject(s)
Interleukin-13/physiology , Respiratory Hypersensitivity/immunology , Airway Resistance , Allergens/administration & dosage , Animals , Bronchoalveolar Lavage Fluid/immunology , Cytokines/biosynthesis , Female , Goblet Cells/pathology , Hyperplasia , Immunoglobulin Fc Fragments/pharmacology , Immunoglobulins/biosynthesis , Inflammation/pathology , Interleukin-13/antagonists & inhibitors , Lung Compliance , Mice , Mice, Inbred BALB C , Ovalbumin/administration & dosage , Ovalbumin/immunology , Receptors, Interleukin , Recombinant Fusion Proteins/pharmacology , Respiratory Hypersensitivity/etiology , Respiratory Hypersensitivity/pathology , Respiratory Hypersensitivity/physiopathology , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...